Eli Lilly Reports Strong Q1 Results and Raises Full-Year Guidance
Eli Lilly and Company (LLY) reported first-quarter results that exceeded analyst expectations, with revenue rising 56% year-over-year to $19.8 billion. The company also raised its full-year 2026 revenue guidance and shares rose more than 5% in premarket trading.
Tickers: $LLY
Topics: Earnings FDA Approval Guidance Upgrade Revenue Growth Stock Price Movement